Autoimmune hepatitis incidence has increased notably in older adults, with higher prevalence and better treatment response, often presenting with milder symptoms.
Infliximab shows positive results in autoimmune hepatitis resistant to conventional therapies, improving liver function in most patients and representing a potential future treatment option.
Autoimmune liver disease occurs when the immune system attacks the liver, leading to inflammation and damage. Although its cause is unclear, viruses, vaccines, and antibiotics may trigger it. Early diagnosis is essential to managing and treating this potentially severe condition.
A recent study in The Lancet reveals that prevalence has tripled since 2000, with a notable increase in women and over 65 years
Regarding liver diseases, no direct relationship or increased risk of coronavirus infection is established.
The frequency of autoimmune hepatitis is increasing in recent years. Its correct diagnosis and treatment is essential to prevent the progression of liver damage